Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Current Assets (2019 - 2026)

C4 Therapeutics has reported Current Assets over the past 8 years, most recently at $245.4 million for Q1 2026.

  • For Q1 2026, Current Assets rose 5.52% year-over-year to $245.4 million; the TTM value through Mar 2026 reached $245.4 million, up 5.52%, while the annual FY2025 figure was $258.1 million, 0.13% changed from the prior year.
  • Current Assets for Q1 2026 was $245.4 million at C4 Therapeutics, down from $258.1 million in the prior quarter.
  • Over five years, Current Assets peaked at $325.5 million in Q3 2022 and troughed at $206.9 million in Q3 2025.
  • A 5-year average of $266.8 million and a median of $273.2 million in 2024 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: crashed 33.34% in 2022 and later increased 22.15% in 2024.
  • Year by year, Current Assets stood at $287.6 million in 2022, then fell by 5.69% to $271.2 million in 2023, then decreased by 4.95% to $257.8 million in 2024, then rose by 0.13% to $258.1 million in 2025, then decreased by 4.94% to $245.4 million in 2026.
  • Business Quant data shows Current Assets for CCCC at $245.4 million in Q1 2026, $258.1 million in Q4 2025, and $206.9 million in Q3 2025.